相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
A Population based Study Evaluating the Impact of Sunitinb on Overall Survival in the Treatment of Patients With Metastatic Renal Cell Cancer
Daniel Y. C. Heng et al.
CANCER (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer
Shu Yang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2008)
Imaging in metastatic renal cell carcinoma
Nyree Griffin et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Xenografts of human hepatocellular carcinoma: A useful model for testing drugs
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2006)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer
MA Rochester et al.
CANCER GENE THERAPY (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
A Zisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes
P Bouillet et al.
NATURE (2002)
Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release
J Whitfield et al.
NEURON (2001)
Molecular mechanisms of blood vessel growth
EM Conway et al.
CARDIOVASCULAR RESEARCH (2001)
分享论文
